BSE Live
Apr 17, 16:01Prev. Close
1766.45
Open Price
1793.30
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 17, 15:57Prev. Close
1764.90
Open Price
1764.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1770.90 (57)
| Cash Flow of Caplin Point Laboratories (in Rs. Cr.) | Jun 05 | Mar 04 | |
| 15 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 0.71 | 0.22 | |
| Net CashFlow From Operating Activities | 0.83 | 0.10 | |
| Net Cash Used In Investing Activities | -0.83 | -0.02 | |
| Net Cash Used From Financing Activities | 0.00 | -0.03 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 0.00 | 0.04 | |
| Cash And Cash Equivalents Begin of Year | 0.08 | 0.04 | |
| Cash And Cash Equivalents End Of Year | 0.08 | 0.08 |
10.02.2026
Caplin Labs Consolidated December 2025 Net Sales at Rs 542.77 crore, up 10.1% Y-o-Y
09.02.2026
Caplin Labs Standalone December 2025 Net Sales at Rs 189.22 crore, up 2.15% Y-o-Y
12.11.2025
Caplin Labs Standalone September 2025 Net Sales at Rs 175.18 crore, down 15.75% Y-o-Y
05.11.2025
Caplin Labs Consolidated September 2025 Net Sales at Rs 534.04 crore, up 10.54% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth